TY - JOUR
T1 - Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia
AU - Yakimchuk, Konstantin
AU - Norin, Stefan
AU - Kimby, Eva
AU - Hägglund, Hans
AU - Warner, Margaret
AU - Gustafsson, Jan Åke
N1 - Funding Information:
This work was supported by grants from the Swedish Cancer Fund and from the Robert A Welch Foundation.
Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/1
Y1 - 2012/1
N2 - The estrogen receptors alpha (ERα) and beta (ERβ) have been demonstrated in mouse models to be important for immune system regulation, and are differentially expressed in lymphoid organs. One ERβ splice variant, ERβ2, inhibits the ERα-mediated estrogen effect, and expression might predict response to selective estrogen receptor modulators. We studied the expression of ERα, ERβ1 and ERβ2 in peripheral blood mononuclear cells from 26 patients with chronic lymphocytic leukemia (CLL) and 30 normal controls using immunocytochemistry. ERα expression was generally low, while ERβ1 was expressed in 65% of patients with CLL and in 83% of controls (NS). In contrast, nuclear staining for ERβ2 was positive in 69% of patients with CLL, but in only 17% of controls (p < 0.001). In CLL, ERβ2 was found in B- but not in T-lymphocytes. Our data show the expression of ERβ1 and ERβ2 in the majority of patients with CLL, suggesting that the ERs are important in CLL and might be used as therapeutic targets.
AB - The estrogen receptors alpha (ERα) and beta (ERβ) have been demonstrated in mouse models to be important for immune system regulation, and are differentially expressed in lymphoid organs. One ERβ splice variant, ERβ2, inhibits the ERα-mediated estrogen effect, and expression might predict response to selective estrogen receptor modulators. We studied the expression of ERα, ERβ1 and ERβ2 in peripheral blood mononuclear cells from 26 patients with chronic lymphocytic leukemia (CLL) and 30 normal controls using immunocytochemistry. ERα expression was generally low, while ERβ1 was expressed in 65% of patients with CLL and in 83% of controls (NS). In contrast, nuclear staining for ERβ2 was positive in 69% of patients with CLL, but in only 17% of controls (p < 0.001). In CLL, ERβ2 was found in B- but not in T-lymphocytes. Our data show the expression of ERβ1 and ERβ2 in the majority of patients with CLL, suggesting that the ERs are important in CLL and might be used as therapeutic targets.
KW - Lymphocytes
KW - Lymphoid leukemia
KW - Pharmacotherapeutics
UR - http://www.scopus.com/inward/record.url?scp=84855454903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855454903&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.605187
DO - 10.3109/10428194.2011.605187
M3 - Article
C2 - 21767241
AN - SCOPUS:84855454903
SN - 1042-8194
VL - 53
SP - 139
EP - 144
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -